Brincidofovir: Additional Phase III data

Additional data from the double-blind, international Phase III SUPPRESS trial in 452 CMV-seropositive hematopoietic stem cell transplant (HSCT) recipients showed that 51% of patients who received twice-weekly 100 mg oral brincidofovir had clinically significant CMV infection at week 24, the primary endpoint, vs.